Shuttle Pharmaceuticals Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Chris Cooper

İcra Kurulu Başkanı

US$240.0k

Toplam tazminat

CEO maaş yüzdesi	80.65%
CEO görev süresi	1.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	7.2yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Sep 15

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Newly public Shuttle Pharmaceuticals (NASDAQ:SHPH) on Thursday said it had been awarded patents in the U.S. and Hong Kong for its technology platform which reduces side effects for cancer patients treated with radiation therapy. The awarded patents were for SHPH's radiation sensitizing HDAC inhibitor technology platform, the company said in a statement. Histone deacetylase (HDAC) inhibitors are a class of drugs that target enzymes involved in the regulation of cellular functions that can inhibit cancer growth. The patents awarded were U.S. patent no. 11,407,723 and Hong Kong patent no. HK1250474, SHPH said, with European applications also under review. Shares of Shuttle Pharmaceuticals (SHPH) were 44.8% lower at $20.68 in mid-day trading, continuing their wild post-IPO ride. SHPH went public on Aug. 31, where it soared more than 300%, and has posted extreme swings in both negative and positive territories since then.

CEO Tazminat Analizi

Chris Cooper'un ücretlendirmesi Shuttle Pharmaceuticals Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$11m
Dec 31 2025	US$240k	US$194k	-US$12m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 240.00K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 653.62K ).

Tazminat ve Kazançlar: Chris şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Chris Cooper (56 yo)

1.1yrs

Görev süresi

US$240,001

Tazminat

Mr. Christopher Robert Cooper, also known as Chris, MBA, is CFO & Corporate Secretary of Arcus Development Group Inc. from April 09, 2026. He is CEO of Akanda Corp. from September 3, 2026. He is Independen...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Cooper	Interim Co-CEO & Director	no data	US$240.00k	Veri yok
Milton Brown	Co-Founder	13.8yrs	US$4.17k	Veri yok
Ryan Trasolini	Co-Chief Executive Officer	less than a year	Veri yok	Veri yok
Mira Jung	Co-Founder & Chief Scientific Officer for Biology	13.8yrs	Veri yok	0.093% $ 1.9k
Yuying Liang	Chief Financial Officer	less than a year	Veri yok	Veri yok
Tyvin Rich	Chief Clinical Officer & Chief Medical Officer	no data	US$218.00k	0.00017% $ 3.4
Michael Vander Hoek	Vice President for Operations and Regulatory	no data	US$548.47k	0.0089% $ 179.5

7.2yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim: SHPH 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Cooper	Interim Co-CEO & Director	1.1yrs	US$240.00k	Veri yok
Theodore Phillips	Chairman of Scientific Advisory Committee	8.7yrs	US$93.70k	Veri yok
Ralph Weichselbaum	Member of Scientific Advisory Committee	13.7yrs	Veri yok	Veri yok
J. Brown	Member of Scientific Advisory Committee	9.7yrs	Veri yok	Veri yok
George Scorsis	Independent Chairman of the Board	1.6yrs	US$226.83k	Veri yok
Joseph Armstrong	Member of Scientific Advisory Committee	5.7yrs	Veri yok	Veri yok
Alejandro Villagra	Member of Scientific Advisory Committee	9.7yrs	Veri yok	Veri yok
Angel Liriano	Independent Director	1yr	US$7.57k	Veri yok
Adam Chambers	Director	1yr	US$7.85k	Veri yok

5.7yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SHPH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/15 22:28
Gün Sonu Hisse Fiyatı	2026/09/15 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Shuttle Pharmaceuticals Holdings, Inc. 0 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Shuttle Pharmaceuticals Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 21, 2026

Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes, Effective November 21, 2025

Less than half of directors are independent

Shuttle Pharmaceuticals Holdings, Inc. Appoints George Scorsis as Chairman of the Board of Directors

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 09, 2025

Recent updates

Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of Nasdaq Noncompliance Letter

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharma Announces Reverse Stock Split as Part of its Strategic Plan to Maintain Compliance with Nasdaq's Continued Listing Requirements

High number of new and inexperienced directors

Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $11 million in funding

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 21, 2026

Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3.500001 million.

New major risk - Share price stability

Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes, Effective November 21, 2025

Shuttle Pharmaceuticals Regains Nasdaq Compliance

Less than half of directors are independent

Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4.249998 million in funding from Lytham Partners, LLC

Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $4.251157 million in funding

New major risk - Share price stability

Shuttle Pharmaceuticals Holdings, Inc. Appoints George Scorsis as Chairman of the Board of Directors

New major risk - Financial position

Shuttle Pharmaceuticals Holdings, Inc. Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 09, 2025

Shuttle Pharmaceuticals Provides Update Regarding Minimum Equity Requirement of Nasdaq

Shuttle Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5.732174 million.

Shuttle Pharmaceuticals Holdings, Inc. Appoints Christopher Cooper as Interim Co-CEO

Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

New major risk - Negative shareholders equity

Shuttle Pharmaceuticals Holdings, Inc. Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in funding

Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c)

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303

Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024

New major risk - Financial position

New major risk - Financial position

New minor risk - Share price stability

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

New minor risk - Share price stability

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform

Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

New major risk - Financial position

Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing Rules

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLC

Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for Cancer

Insufficient new directors

Shuttle Pharmaceuticals Holdings, Inc. Appoints Bette Jacobs to Its Board of Directors

Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer Treatment

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million.

CEO Tazminat Analizi

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları